ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学内発行雑誌
  2. The Showa University journal of medical sciences
  3. Vol.29(2017)
  4. No.1

On-demand Inhaled Corticosteroid and Fast-onset Beta-2 Agonist Combination Therapy Versus Conventional Treatment for Mild to Moderate Asthma: A Non-inferiority, Network Meta-analysis

https://showa.repo.nii.ac.jp/records/523
https://showa.repo.nii.ac.jp/records/523
ac46a03e-8134-4771-858e-bb4f0065fb68
名前 / ファイル ライセンス アクション
S29_17.pdf S29_17.pdf (467.4 kB)
Item type 学内発行雑誌 / Departmental Bulletin Paper(1)
公開日 2017-12-01
タイトル
タイトル On-demand Inhaled Corticosteroid and Fast-onset Beta-2 Agonist Combination Therapy Versus Conventional Treatment for Mild to Moderate Asthma: A Non-inferiority, Network Meta-analysis
言語 en
言語
言語 eng
資源タイプ
資源タイプ departmental bulletin paper
著者 ANDO, Koichi

× ANDO, Koichi

ANDO, Koichi

Search repository
TANAKA, Akihiko

× TANAKA, Akihiko

TANAKA, Akihiko

Search repository
YOKOE, Takuya

× YOKOE, Takuya

YOKOE, Takuya

Search repository
OHNISHI, Tsukasa

× OHNISHI, Tsukasa

OHNISHI, Tsukasa

Search repository
INOUE, Shin

× INOUE, Shin

INOUE, Shin

Search repository
SAGARA, Hironori

× SAGARA, Hironori

SAGARA, Hironori

Search repository
書誌情報 The Showa University journal of medical sciences

巻 29, 号 1, p. 17-26, 発行日 2017-03
抄録
内容記述タイプ Abstract
内容記述 The aim of this study was to assess the non-inferiority of on-demand (OD) inhaled corticosteroid (ICS) and fast-onset beta-2 agonist (FOBA) combination therapy. Although the guidelines recommend regular inhalation of ICS and long-acting beta-2 agonist (LABA), we investigated whether OD-ICS/FOBA is as effective as regular inhalation. A network meta-analysis of randomized controlled trials was conducted to inspect the non-inferiority of OD-ICS/FOBA efficacy compared with conventional best practice, i.e. regular low – to medium-dose ICS with or without LABA, plus OD short-acting beta-2 agonist (REG-ICS+OD-SABA or REG-ICS/LABA+OD-SABA) in patients with mild to moderate asthma. PubMed, the Cochrane library database, and Scopus were searched to identify relevant articles. Outcome measures were the incidence of asthma exacerbation or aggravation. A network meta-analysis was performed to estimate risk ratios (RRs) with 95% confidence intervals (CIs) and the probability of being the best treatment for the outcome. Four randomized controlled trials of treatment for mild to moderate asthma met the criteria and were included in the study. We could not demonstrate non-inferiority of OD-ICS/FOBA to REG-ICS+OD-SABA (RR, 1.17; 95% CI, 0.61 to 2.26) or to REG-ICS/LABA+OD-SABA (RR, 1.47; 95% CI, 0.79 to 2.71) for mild to moderate asthma. The probability of being the best treatment to reduce asthma exacerbation or aggravation was 10.5% for OD-ICS/FOBA, 10.3% for REG-ICS+OD-SABA, and 79.3% for REG-ICS/LABA+OD-SABA. Surface under the cumulative ranking (SUCRA) curves were 0.4, 0.2 and 0.9 for OD-ICS/FOBA, REG-ICS+OD-SABA, and REG-ICS/LABA+OD-SABA, respectively. Although non-inferiority of OD-ICS/FOBA to conventional best practice was not shown, SUCRA was higher for OD-ICS/FOBA than for REG-ICS+OD-SABA. From these results, we propose that OD-ICS/FOBA can be an effective alternative to REG-ICS+OD-SABA to reduce asthma exacerbation or aggravation in patients with mild to moderate asthma.
DOI
関連タイプ isIdenticalTo
関連識別子 10.15369/sujms.29.17
出版者
出版者 Showa University Society
ISSN
収録物識別子タイプ ISSN
収録物識別子 0915-6380
出版タイプ
出版タイプ VoR
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 12:44:23.873918
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3